A Wild CAR-T Race In China: The Hype, Reality And What Works

 
• By Brian Yang

As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.

DIA panel on CAR-T in China, held in Suzhou Oct. 26, 2018
DIA Panel on CAR-T in China, L to R: Richard Wang of Fosun-Kite, Sun Wenjun of Juno-Wuxi, DIA China MD Carol Zhu, Zhu Li of Genescript, Steve Yang of WuXi Apptec • Source: DIA China

More from China

More from Focus On Asia